More News

13 Feb 2017 Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement
11 Feb 2017 Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
09 Feb 2017 Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area
09 Feb 2017 Aurobindo Pharma Forays into Biosimilars Development through an acquisition of Four Products from TL Biopharmaceutical AG
06 Feb 2017 Isogenica Announces New Licence Agreement with Maverick Therapeutics
03 Feb 2017 UV-Cap GmbH & Co KG acquires Scil Proteins GmbH
02 Feb 2017 Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm
31 Jan 2017 Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections
31 Jan 2017 Exelixis and Takeda enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in Japan
30 Jan 2017 Charles River Laboratories Announces Progress Update for Collaboration with Moderna Therapeutics
30 Jan 2017 Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
30 Jan 2017 Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre
26 Jan 2017 Celgene to Acquire Delinia, Inc.
26 Jan 2017 Johnson & Johnson To Acquire Actelion For $30 Billion With Spin-Out Of New R&D Company
25 Jan 2017 Enteris BioPharma Enters into Agreement with Nordic Bioscience's KeyBioscience to Develop Orally Delivered Metabolic Peptide
25 Jan 2017 Cue Biopharma Debuts With $26 Million in Invested Capital to Develop Next-Generation Biologics to Selectively Control T Cell Activity
25 Jan 2017 WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement
25 Jan 2017 Intrexon to Acquire GenVec
24 Jan 2017 Ewopharma Partners with Biogen to Commercialise BENEPALI® and FLIXABI® in Central Eastern Europe
24 Jan 2017 Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment
24 Jan 2017 Hope Biosciences Licenses nuc-Gemcitabine, A 'Trojan Horse' Anti-nucleolin-Gemcitabine Aptamer Drug Conjugate Against Cancer
23 Jan 2017 Biotest to sell US therapy business to ADMA Biologics, Inc., and will receive approximately 50% of the shares of ADMA Biologics, Inc. at closing, which is anticipated to occur in the first half of 2017
23 Jan 2017 Enteris, Sanofi to Develop Oral Therapeutic for Type 2 Diabetes
23 Jan 2017 Merck Announces Research Collaboration with Domain Therapeutics in Immuno-Oncology
21 Jan 2017 Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing